Curated News
By: NewsRamp Editorial Staff
November 10, 2025

NRx Launches Revolutionary One-Day Depression Treatment in Florida

Discuss on Substack View History of this news story on GitHub
Original Source

TLDR

  • NRx Pharmaceuticals gains first-mover advantage in Florida with its Ampa ONE-D protocol, offering a competitive edge in treating depression with rapid one-day results.
  • The Ampa device combines transcranial magnetic stimulation with D-cycloserine and lisdexamfetamine in a single-day protocol that achieved 87% response rates in clinical studies.
  • This breakthrough treatment transforms depression care from months to one day, potentially improving millions of lives affected by treatment-resistant depression and PTSD.
  • Florida clinics now offer a revolutionary one-day depression treatment using magnetic brain stimulation combined with medications, achieving remarkable 72% remission rates.

Impact - Why it Matters

This development represents a potential paradigm shift in mental health treatment, offering hope to millions suffering from treatment-resistant depression and PTSD. Traditional TMS therapy typically requires daily sessions over several weeks or months, creating significant barriers to access and compliance. The Ampa ONE-D protocol's ability to deliver comparable or superior results in a single day could dramatically reduce treatment burden, lower healthcare costs, and make effective care accessible to more patients. Given that depression affects over 280 million people globally and treatment-resistant cases represent up to 30% of depression patients, this innovation addresses a critical unmet medical need. The high response and remission rates demonstrated in studies suggest this approach could transform outcomes for patients who have exhausted conventional treatment options, potentially reducing suicide risk and improving quality of life for countless individuals and their families.

Summary

NRx Pharmaceuticals (NASDAQ: NRXP), through its subsidiary HOPE Therapeutics™, has launched a groundbreaking treatment for treatment-resistant depression using the innovative Ampa "one day" (ONE-D) protocol. This pioneering approach marks the first deployment of its kind in Florida and represents one of the earliest nationwide implementations. Under the medical direction of Dr. Rebecca Cohen, HOPE clinics in Sarasota, Naples, and Fort Myers are now offering this revolutionary protocol, with plans to expand to six Florida locations by year-end. The Ampa device combines a single day of transcranial magnetic stimulation (TMS) with physician-prescribed D-cycloserine and lisdexamfetamine, creating a powerful combination that has demonstrated remarkable efficacy in peer-reviewed studies.

The clinical results from nonrandomized trials have been exceptionally promising, showing response rates of 87% and remission rates of 72% among patients. Dr. Cohen emphasized that these outcomes "have the potential to change the paradigm of TMS therapy" by transforming what has traditionally been a months-long treatment regimen into a rapid, one-day approach. This breakthrough could significantly impact care for millions of individuals battling depression and PTSD, offering new hope where traditional treatments have failed. The company's broader mission focuses on developing therapeutics based on its NMDA platform for central nervous system disorders, including suicidal depression, chronic pain, and PTSD, with several key products in advanced development stages.

NRx Pharmaceuticals maintains strong relationships within the medical and investment communities, supported by platforms like MissionIR that help enhance visibility and communication. The company's clinical pipeline includes NRX-100, which has received Fast Track Designation for treating Suicidal Ideation in Depression, and NRX-101, awarded Breakthrough Therapy Designation for suicidal bipolar depression. Recent regulatory progress includes filing an Abbreviated New Drug Application and initiating a New Drug Application for NRX-100, positioning the company at the forefront of innovative mental health treatments. For comprehensive updates and detailed information about NRXP, investors and interested parties can access the company's newsroom through the provided links.

Source Statement

This curated news summary relied on content disributed by InvestorBrandNetwork (IBN). Read the original source here, NRx Launches Revolutionary One-Day Depression Treatment in Florida

blockchain registration record for this content.